Skip to main content
Clinical Trials/JPRN-UMIN000025725
JPRN-UMIN000025725
Completed
Phase 2

Evaluation of safety and protective efficacy of fulminant hepatitis to abatacept treatment of patients with HBV-related severe hepatitis.-Pilot Study- - A pilot study of abatacept treatment for HBV fulminant hepatitis prevention.

Hiroshima university hospital0 sites10 target enrollmentFebruary 1, 2017

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
HBV-related acute severe hepatitis
Sponsor
Hiroshima university hospital
Enrollment
10
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 1, 2017
End Date
March 31, 2025
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) PT less than 10% 2\) PT 61% or more, and either AST or ALT is on a downward trend 3\) Hepatic encephalopathy 2 deg rees or more 4\) Patients with autoimmune hepatitis 5\) Patients with a history of hypersensitivity to orencia 6\) Patients with severe infection 7\) In addition, patients judg ed unsuitable for participation in this study by research doctor.

Outcomes

Primary Outcomes

Not specified

Similar Trials